| Mr Daniel Thomas Poole, MD | |
|
2609 Medical Office Pl, Goldsboro, NC 27534-9428 | |
| (919) 734-1779 | |
| (919) 734-7570 |
| Full Name | Mr Daniel Thomas Poole |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 30 Years |
| Location | 2609 Medical Office Pl, Goldsboro, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205875234 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 9801018 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wayne Memorial Hospital | Goldsboro, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Unc Physicians Network | 5496940546 | 709 |
News Archive
A research team at the Ludwig Institute and Uppsala University has discovered an entirely new signal path for a growth factor that is of crucial importance for the survival and growth of cancer cells.
MannKind Corporation has announced that it has initiated patient enrollment in two pivotal 12-month Phase 3 clinical trials of Technosphere Insulin (TI) in patients with Type 1 and Type 2 Diabetes.
Ipsen (Euronext:IPN), an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
AEterna Zentaris Inc., ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc., its partner and licensee for perifosine in the North American market, has received orphan-drug designation for this compound from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma.
Older adults with hearing loss are more likely to develop problems thinking and remembering than older adults whose hearing is normal, according to a new study by hearing experts at Johns Hopkins.
› Verified 3 days ago
| Entity Name | Eastern Medical Associates, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194762807 PECOS PAC ID: 3173414109 Enrollment ID: O20040322000237 |
News Archive
A research team at the Ludwig Institute and Uppsala University has discovered an entirely new signal path for a growth factor that is of crucial importance for the survival and growth of cancer cells.
MannKind Corporation has announced that it has initiated patient enrollment in two pivotal 12-month Phase 3 clinical trials of Technosphere Insulin (TI) in patients with Type 1 and Type 2 Diabetes.
Ipsen (Euronext:IPN), an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
AEterna Zentaris Inc., ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc., its partner and licensee for perifosine in the North American market, has received orphan-drug designation for this compound from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma.
Older adults with hearing loss are more likely to develop problems thinking and remembering than older adults whose hearing is normal, according to a new study by hearing experts at Johns Hopkins.
› Verified 3 days ago
| Entity Name | Unc Physicians Network Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750704367 PECOS PAC ID: 5496940546 Enrollment ID: O20101115000646 |
News Archive
A research team at the Ludwig Institute and Uppsala University has discovered an entirely new signal path for a growth factor that is of crucial importance for the survival and growth of cancer cells.
MannKind Corporation has announced that it has initiated patient enrollment in two pivotal 12-month Phase 3 clinical trials of Technosphere Insulin (TI) in patients with Type 1 and Type 2 Diabetes.
Ipsen (Euronext:IPN), an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
AEterna Zentaris Inc., ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc., its partner and licensee for perifosine in the North American market, has received orphan-drug designation for this compound from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma.
Older adults with hearing loss are more likely to develop problems thinking and remembering than older adults whose hearing is normal, according to a new study by hearing experts at Johns Hopkins.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Daniel Thomas Poole, MD 2609 Medical Office Pl, Goldsboro, NC 27534-9428 Ph: (919) 734-1779 | Mr Daniel Thomas Poole, MD 2609 Medical Office Pl, Goldsboro, NC 27534-9428 Ph: (919) 734-1779 |
News Archive
A research team at the Ludwig Institute and Uppsala University has discovered an entirely new signal path for a growth factor that is of crucial importance for the survival and growth of cancer cells.
MannKind Corporation has announced that it has initiated patient enrollment in two pivotal 12-month Phase 3 clinical trials of Technosphere Insulin (TI) in patients with Type 1 and Type 2 Diabetes.
Ipsen (Euronext:IPN), an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
AEterna Zentaris Inc., ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc., its partner and licensee for perifosine in the North American market, has received orphan-drug designation for this compound from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma.
Older adults with hearing loss are more likely to develop problems thinking and remembering than older adults whose hearing is normal, according to a new study by hearing experts at Johns Hopkins.
› Verified 3 days ago
Dr. Stephanie E Page, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 201 Stevens Mill Rd, Goldsboro, NC 27530 Phone: 919-731-3420 | |
Dr. Zahid Rauf, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1706 Wayne Memorial Dr, Goldsboro, NC 27534 Phone: 919-734-6676 Fax: 919-734-9050 | |
Jennifer A. Quinn, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: Cherry Hospital, 1401 West Ash Street, Goldsboro, NC 27530 Phone: 919-731-3206 | |
Teresa Tracy, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 817 Mill Rd, Goldsboro, NC 27534 Phone: 913-980-5370 | |
Ramaswamy Vellore Sriraman, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1706 Wayne Memorial Dr, Goldsboro, NC 27534 Phone: 919-734-6676 Fax: 919-734-9050 | |
Raye Mimi Zhu, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1401 W Ash St, Goldsboro, NC 27530 Phone: 919-947-7000 | |
Dr. Ralph Roger Berg Jr., M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1503 Wayne Memorial Dr, Suite H, Goldsboro, NC 27534 Phone: 919-330-4367 Fax: 919-330-4375 |